Kiora Pharmaceuticals
KPRX
17 hedge funds and large institutions have $425K invested in Kiora Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
50% more capital invested
Capital invested by funds: $284K → $425K (+$142K)
21% more funds holding
Funds holding: 14 → 17 (+3)
0.68% more ownership
Funds ownership: 0.48% → 1.16% (+0.68%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$727K |
| 2 |
Walleye Capital
New York
|
+$583K |
| 3 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$46.6K |
| 4 |
HF
HRT Financial
New York
|
+$31.4K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$28.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$47.2K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$40.9K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$40.4K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$4.28K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$356 |
KPRX Hedge Fund Activity: Q2 2023 in Review
17 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q2 2023, worth a combined $425K — up 50% from $284K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new KPRX positions and 3 closed out — a net gain of 3 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $727K. The largest seller was Citadel Advisors, exiting entirely with an estimated $47.2K sold.
- 17 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q2 2023, up from 14 in Q1 2023.
- Funds reported $425K of Kiora Pharmaceuticals stock for Q2 2023, up 50% quarter-over-quarter.
- 6 funds opened new Kiora Pharmaceuticals positions in Q2 2023 and 3 closed out, a net change of +3 holders.
- The largest Kiora Pharmaceuticals buyer in Q2 2023 was Sabby Management, an estimated $727K added.
- The largest Kiora Pharmaceuticals seller in Q2 2023 was Citadel Advisors, an estimated $47.2K sold.
Based on aggregated 13F filings for Q2 2023.